MarketResearchNest.com adds “Global Dengue Vaccine Market 2017-2021” new reports to its research database. The report spread across 78 pages with tables and figures in it.
The analysts forecast the global dengue vaccine market to grow at a CAGR of 15.05% during the period 2017-2021.
The Aedes aegypti mosquito is responsible for transmitting the dengue virus (DENV). The virus that causes dengue belongs to the Flavivirus genus of the Flaviviridae family. Dengue fever resembles influenza and affects adults, children, as well as infants, but it is rarely fatal. However, dengue hemorrhagic fever is a potentially fatal complication because of multiple factors such as fluid accumulation, severe bleeding, organ impairment, or plasma leaking. The scientific community hypothesizes that the DENV evolved in nonhuman primates from where it spread to humans first in Southeast Asia and Africa and then to other parts of the world.
Get more details about report at https://www.marketresearchnest.com/global-dengue-vaccine-market-2017-2021.html .
Technavio recognizes the following companies as the key players in the global dengue vaccine market: GlaxoSmithKline, Merck Sharp & Dohme, Sanofi, and Takeda Pharmaceuticals.
Other Prominent Vendors in the market are: GeneOne Life Sciences, Medigen Biologics, Panacea Biotec, and Sun Pharmaceutical.
Commenting on the report, an analyst team said: “One trend in the market is licensing deals. Companies are increasingly focused on developing novel and effective dengue vaccines. Toward that effort, they are engaging in partnerships and collaborations with other market players. Several licensing deals have taken place in the global dengue vaccine market.”
Request a Sample Copy at https://www.marketresearchnest.com/requestsample.php?reportid=283161 .
According to the report, one driver in the market is rapid growth in disease prevalence. The prevalence of dengue is rising rapidly. The factors contributing to the rise in dengue cases include an increase in population density and global warming. As per the NIH, 3.6 billion people that reside in tropical and subtropical regions are at risk of dengue transmission. Global estimates vary, but nearly 0.05 to 0.2 billion cases of dengue infections are reported annually. In 2011, annual cases of severe dengue were around 0.5 million, and mortality due to dengue was above 20,000 as per the NIH. As per the NIH, in 2012, the upper bound total was 3.97 billion for people at risk of dengue in 128 countries globally.
Further, the report states that one challenge in the market is regulatory hurdles in vaccine penetration. Vendors are facing difficulty in getting approvals for the launch of vaccines in several dengue-endemic countries due to the nature of dengue serotypes in different countries. The circulation of dengue serotypes fluctuates in dengue-endemic regions. Hence, vaccine efficacy must be exhibited against all four serotypes for which region-specific clinical trials are required to be conducted. For the inclusion of vaccines in the public immunization program of any country, demographic efficacy and safety data are required, which require additional clinical trials at regional levels at times to comply with the regulatory requirements. This leads to delay in the launch of the product, and ultimately the potential sales get affected negatively.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=283161 .
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain
+1-240-284-8070 / +44-20-3290-4151